 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Nov 04, 2022 |
| Title |
Drug screening identifies tazarotene and bexarotene as therapeutic agents in Multiple Sulfatase Deficiency |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
We analysed differences in gene expression upon treatment of MSD patient fibroblast lines with either tazarotene or adapalene and DMSO control (untreated condition)
|
| |
|
| Overall design |
Comparative gene expression profiling analysis of RNA-seq data
|
| |
|
| Contributor(s) |
Schröder S, Pena-Centeno T, Fischer A, Schlotawa L |
| Citation(s) |
36789546 |
| Submission date |
Jun 06, 2022 |
| Last update date |
Feb 17, 2023 |
| Contact name |
Andre Fischer |
| Organization name |
German Center for Neurodegenerative Diseases (DZNE)
|
| Department |
Epigenetic Mechanisms in Dementia
|
| Lab |
AG-Fischer
|
| Street address |
Von Sieboldstr 3a
|
| City |
Gottingen |
| State/province |
NS |
| ZIP/Postal code |
37075 |
| Country |
Germany |
| |
|
| Platforms (1) |
|
| Samples (62)
|
| GSM6214563 |
Human MSD patient fibroblast line A, adapalene treatment, 6 days, rep1 |
| GSM6214564 |
Human MSD patient fibroblast line A, adapalene treatment, 6 days, rep2 |
| GSM6214565 |
Human MSD patient fibroblast line A, adapalene treatment, 6 days, rep3 |
| GSM6214566 |
Human MSD patient fibroblast line A, DMSO treatment, 6 days, rep1 |
| GSM6214567 |
Human MSD patient fibroblast line A, DMSO treatment, 6 days, rep2 |
| GSM6214568 |
Human MSD patient fibroblast line A, DMSO treatment, 6 days, rep3 |
| GSM6214569 |
Human MSD patient fibroblast line A, tazarotene treatment, 6 days, rep1 |
| GSM6214570 |
Human MSD patient fibroblast line A, tazarotene treatment, 6 days, rep2 |
| GSM6214571 |
Human MSD patient fibroblast line A, tazarotene treatment, 6 days, rep3 |
| GSM6214572 |
Human MSD patient fibroblast line B, adapalene treatment, 6 days, rep1 |
| GSM6214573 |
Human MSD patient fibroblast line B, adapalene treatment, 6 days, rep2 |
| GSM6214574 |
Human MSD patient fibroblast line B, adapalene treatment, 6 days, rep3 |
| GSM6214575 |
Human MSD patient fibroblast line B, DMSO treatment, 6 days, rep1 |
| GSM6214576 |
Human MSD patient fibroblast line B, DMSO treatment, 6 days, rep2 |
| GSM6214577 |
Human MSD patient fibroblast line B, tazarotene treatment, 6 days, rep1 |
| GSM6214578 |
Human MSD patient fibroblast line B, tazarotene treatment, 6 days, rep2 |
| GSM6214579 |
Human MSD patient fibroblast line B, tazarotene treatment, 6 days, rep3 |
| GSM6214580 |
Human MSD patient fibroblast line C, adapalene treatment, 6 days, rep1 |
| GSM6214581 |
Human MSD patient fibroblast line C, adapalene treatment, 6 days, rep2 |
| GSM6214582 |
Human MSD patient fibroblast line C, adapalene treatment, 6 days, rep3 |
| GSM6214583 |
Human MSD patient fibroblast line C, DMSO treatment, 6 days, rep1 |
| GSM6214584 |
Human MSD patient fibroblast line C, DMSO treatment, 6 days, rep2 |
| GSM6214585 |
Human MSD patient fibroblast line C, DMSO treatment, 6 days, rep3 |
| GSM6214586 |
Human MSD patient fibroblast line C, tazarotene treatment, 6 days, rep1 |
| GSM6214587 |
Human MSD patient fibroblast line C, tazarotene treatment, 6 days, rep2 |
| GSM6214588 |
Human MSD patient fibroblast line C, tazarotene treatment, 6 days, rep3 |
| GSM6214589 |
Human MSD patient fibroblast line D, adapalene treatment, 6 days, rep1 |
| GSM6214590 |
Human MSD patient fibroblast line D, adapalene treatment, 6 days, rep2 |
| GSM6214591 |
Human MSD patient fibroblast line D, adapalene treatment, 6 days, rep3 |
| GSM6214592 |
Human MSD patient fibroblast line D, DMSO treatment, 6 days, rep1 |
| GSM6214593 |
Human MSD patient fibroblast line D, DMSO treatment, 6 days, rep2 |
| GSM6214594 |
Human MSD patient fibroblast line D, DMSO treatment, 6 days, rep3 |
| GSM6214595 |
Human MSD patient fibroblast line D, tazarotene treatment, 6 days, rep1 |
| GSM6214596 |
Human MSD patient fibroblast line D, tazarotene treatment, 6 days, rep2 |
| GSM6214597 |
Human MSD patient fibroblast line D, tazarotene treatment, 6 days, rep3 |
| GSM6214598 |
Human MSD patient fibroblast line E, adapalene treatment, 6 days, rep1 |
| GSM6214599 |
Human MSD patient fibroblast line E, adapalene treatment, 6 days, rep2 |
| GSM6214600 |
Human MSD patient fibroblast line E, adapalene treatment, 6 days, rep3 |
| GSM6214601 |
Human MSD patient fibroblast line E, DMSO treatment, 6 days, rep1 |
| GSM6214602 |
Human MSD patient fibroblast line E, DMSO treatment, 6 days, rep2 |
| GSM6214603 |
Human MSD patient fibroblast line E, DMSO treatment, 6 days, rep3 |
| GSM6214604 |
Human MSD patient fibroblast line E, tazarotene treatment, 6 days, rep1 |
| GSM6214605 |
Human MSD patient fibroblast line E, tazarotene treatment, 6 days, rep2 |
| GSM6214606 |
Human MSD patient fibroblast line E, tazarotene treatment, 6 days, rep3 |
| GSM6214607 |
Human MSD patient fibroblast line F, adapalene treatment, 6 days, rep1 |
| GSM6214608 |
Human MSD patient fibroblast line F, adapalene treatment, 6 days, rep2 |
| GSM6214609 |
Human MSD patient fibroblast line F, adapalene treatment, 6 days, rep3 |
| GSM6214610 |
Human MSD patient fibroblast line F, DMSO treatment, 6 days, rep1 |
| GSM6214611 |
Human MSD patient fibroblast line F, DMSO treatment, 6 days, rep2 |
| GSM6214612 |
Human MSD patient fibroblast line F, DMSO treatment, 6 days, rep3 |
| GSM6214613 |
Human MSD patient fibroblast line F, tazarotene treatment, 6 days, rep1 |
| GSM6214614 |
Human MSD patient fibroblast line F, tazarotene treatment, 6 days, rep2 |
| GSM6214615 |
Human MSD patient fibroblast line F, tazarotene treatment, 6 days, rep3 |
| GSM6214616 |
Human MSD patient fibroblast line G, adapalene treatment, 6 days, rep1 |
| GSM6214617 |
Human MSD patient fibroblast line G, adapalene treatment, 6 days, rep2 |
| GSM6214618 |
Human MSD patient fibroblast line G, adapalene treatment, 6 days, rep3 |
| GSM6214619 |
Human MSD patient fibroblast line G, DMSO treatment, 6 days, rep1 |
| GSM6214620 |
Human MSD patient fibroblast line G, DMSO treatment, 6 days, rep2 |
| GSM6214621 |
Human MSD patient fibroblast line G, DMSO treatment, 6 days, rep3 |
| GSM6214622 |
Human MSD patient fibroblast line G, tazarotene treatment, 6 days, rep1 |
| GSM6214623 |
Human MSD patient fibroblast line G, tazarotene treatment, 6 days, rep2 |
| GSM6214624 |
Human MSD patient fibroblast line G, tazarotene treatment, 6 days, rep3 |
|
| Relations |
| BioProject |
PRJNA846323 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE205555_RAW.tar |
14.5 Mb |
(http)(custom) |
TAR (of TXT) |
SRA Run Selector |
| Raw data are available in SRA |
| Processed data provided as supplementary file |
|
|
|
|
 |
Less...
More...